NCT04919811 Phase 2 Active not recruiting
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC Study sponsor: Nuvation Bio Inc. · NUVB
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2025-06-11 Actual
Enrollment · participants 217 Actual
Source updated 2026-01-07 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2025-10-16 · 5 fields changed
Participant count type changed
Enrollment · participant count changed
− Before 224 participants (planned)
+ After 217 participants (actual)
Completion date type changed
Primary completion date changed
Recruitment status changed
+ After Active not recruiting
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial